Protagonist Therapeutics, Inc (PTGX)
Nasdaq · Common stock · Pharmaceutical Preparations
As of Oct 21, 2:18 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow PTGX in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on PTGX and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
PTGX at a glance
Key statistics
$8.93B
Market capitalization
- Previous close
- $137.99
- Open
- $137.85
- Day range
- $137.82 – $141.40
- Volume
- 328.6K
- Average volume (30 sessions)
- 791.4K
- Shares outstanding
- 64.71M
- Price / earnings
- 107.7
- Earnings per share
- $1.28
- Price / book
- 10.6
- Price / sales
- 31.7
- Beta (1 year, vs SPY)
- 0.87
Where the price sits in its year
52-week range
76% of the range
- Below the 52-week high
- -13.1%
- Above the 52-week low
- +91.2%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day average, above its 200-day
- 20-day average
- $139.14-0.8%
- 50-day average
- $144.92-4.8%
- 200-day average
- $114.26+20.8%
Between the conventional 30 and 70 bands.
-0.4%
1 week
-4.8%
1 month
+1.9%
3 months
+58.0%
Year to date
+78.1%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with PTGX
PTGX on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on PTGX.
See the plans →
Every planScreen names like PTGX
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on PTGX
Put PTGX on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on PTGX
See whether there is an open premium alert on PTGX, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
PTGX headlines
- Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie
Benzinga · Mar 19, 2026
- Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Benzinga · Oct 10, 2025
- Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
Benzinga · Sep 17, 2025
- Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Benzinga · Mar 3, 2025
- The Latest Analyst Ratings for Protagonist Therapeutics
Benzinga · Nov 3, 2023
- What 6 Analyst Ratings Have To Say About Protagonist Therapeutics
Benzinga · Sep 25, 2023
- Expert Ratings for Protagonist Therapeutics
Benzinga · Jul 6, 2023
- Where Protagonist Therapeutics Stands With Analysts
Benzinga · Jun 12, 2023
SEC Form 4, most recent first
Insider filings
Ali Asif
+28.4K
Chief Financial Officer · Option exercise
$666.02K · Sep 30, 2026
Ali Asif
+9.2K
Chief Financial Officer · Option exercise
$359.75K · Sep 30, 2026
Ali Asif
+5.3K
Chief Financial Officer · Option exercise
$64.65K · Sep 30, 2026
Ali Asif
−12.6K
Chief Financial Officer · Open-market sale
$1.79M · Sep 30, 2026
Ali Asif
−46.0K
Chief Financial Officer · Open-market sale
$6.53M · Sep 30, 2026
Ali Asif
−15.7K
Chief Financial Officer · Option exercise
· Sep 30, 2026
Ali Asif
−28.4K
Chief Financial Officer · Option exercise
· Sep 30, 2026
Ali Asif
−9.2K
Chief Financial Officer · Option exercise
· Sep 30, 2026
About Protagonist Therapeutics, Inc
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Pharmaceutical Preparations
- Headquarters
- Newark, CA
- Employees
- 141
- Listed since
- Aug 11, 2016
- Website
- protagonist-inc.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.